Table 1.
Summary of Select Studies Using Midodrine for Various Indications in Patients with Liver Cirrhosis
| Indication | Reference | Concomitant drugs | Results |
|---|---|---|---|
| Type 1 HRS | Angeli P, et al10 | Octreotide, albumin | Effective |
| Wong F, et al11 | Octreotide, albumin | Reduction of serum creatinine level | |
| Type 2 HRS | Angeli P, et al9 | Modest effect on SH No effect on RF |
|
| Natriuretic effect | Kalambokis G, et al5 | Improved SH and sodium excretion | |
| Misra VL, et al13 | IV furosemide | No increase in natriuretic response to furosemide | |
| PICD | Singh V, et al6 | As effective as albumin | |
| Appenrodt B, et al12 | Not as effective as albumin | ||
| Refractory ascites | Tandon P, et al4 | Octreotide, albumin | Reduction in the volume of ascites removed No effect on RF Reversible deterioration in MELD score |
| Post-LT renal outcomes | Rice J P, et al14 | Octreotide, albumin | Pre-LT treatment did not have superior post-LT renal function |
- HRS
hepatorenal syndrome
- IV
intravenous
- LT
liver transplantation
- MELD
Model for End-Stage Liver Disease
- PICD
paracentesis-induced circulatory dysfunction
- RF
renal function
- SH
systemic hemodynamic.